We investigated the temporal and spatial distribution of os-teon& during human embryonic and f e d development, using in situ hybridization and immunohistochemistry. Osteonectin gene expression was generally found in cells exhibiting high rates of matrix productionlproliferation. In mineralized tissue, a strong signal was obtained in osteoblasts, odontoblasts, and chondrocytes of the upper hypertrophic and proliferative zones. Chondrocytes of the mineralized zone showed no expression throughout the Werent stages of development. Strong osteonectin expression was found in odontoblasts of developing teeth. In addition, osteonectin mRNA and protein were detected in several nonmineralized tissues: steroid-producing cells of the adrenal
Introduction
Osteonectin is a secreted Ca++ binding glycoprotein which is one of the most abundant non-collagenous proteins in developing bone. As indicated by molecular cloning and peptide analysis, osteonectin is identical to SPARC (secreted protein, acidic, rich in cysteine), a protein initially described as a product of the parietal endodermal cells during mouse development (Bolander et al., 1988; Holland et al., 1987; Mason et al., 1986) . Osteonectin is also identical to a 43 KD protein secreted by epithelial cells in culture (Sage et al., 1984) and to BM 40, a protein produced by the murine Englebreth-Holm-Swarm basement membrane tumor (Dziadek et al., 1986) . The initial description of osteonectin as one of the major non-collagenous proteins of bovine bone matrix and its high S i i t y for calcium and collagen led to the suggestion that osteonectin promotes mineralization by initiating the deposition of hydroxyapatite on the surface of collagen fibrils (Termine et al., 1981) . However, in subsequent studies osteonectin was shown to inhibit rather than to promote the formation of hydroxyapatite (Doi et al., 1989; Romberg et al., 1985) . The widespread distribution of osteonectin observed in non-mineralized murine tissues (Sage et al., 1989a; Holland et al., 1987) argues against a specific role for this protein gland and the gonads, kidney (glomeruli) , lung (bronchi), skin, megacaryocgtes, and large vessels. Histochemistry confumed the results and detected extracellular osteonectin in bone and in the zone of mineralized cartilage only. The localization of osteon& in bone, cartilage, and teeth is consistent with a role in the initiation of mineralization. However, the organ-specific distribution in non-mineralized tissues suggests an important multifunction role of this protein during human development. (]Hisrochem Cyrochem KEY WORDS: Osteonectin; SPARC; Gene expression; Bone; Cartilage; Human morphogenesis. :283-291, 1992) limited to the initiation of mineralization. Recent studies (Lane and Sage, 1990) have identified osteonectin as a potent inhibitor of cell spreading. Therefore, osteonectin may function as a growth regulating factor in tissues undergoing changes in remodeling and/or morphogenesis, possibly via its Ca'+-dependent affinity.
4O
Despite extensive data on osteonectin expression during murine and avian embryogenesis (Pacifici et al., 1990; Sage et al., 1989a; Nomura et al., 1988; Holland et al., 1987) , information on the function and expression of osteonectin in human tissue is scarce. Immunohistochemical data have limited its distribution to mineralized tissue of bone and cartilage Uundt et al., 1987) , but mRNA analysis has suggested a widespread distribution comparable to that in murine tissue (Metsaranta et al., 1989) . To clarify the role of osteonectin during human embryo-and fetogenesis, we have combined immunohistochemical and in situ hybridization techniques to look at gene expression and gene product in various human tissues at different developmental stages.
Materials and Methods
Embryology. Intact human embryos of Carnegie Stage 17-23 (41-56 days post conception) were obtained after therapeutic abortion using prostaglandin pessaries. Embryonic stage was determined by morphological appearance, weight, and crown-rump length. In addition, material of 7-12 weeks gestational age after suction termination and autopsy material from later stages and newborns were analyzed. The tissue was fixed in 4% formalin in PBS and was then processed for paraffin embedding (immuno-histochemistry) or snap-frozen (in situ hybridization) as described earlier (Mundlos et al., 1990) . Mineralized tissue was decalcified in 0.2 N HCI for 1-4 days (Becker et al., 1986) .
Probes and Antibody. The cDNA used (HON-2) had a length of 2450 BP coding for the complete human osteonectin (Young et al., 1990) . The probe shows no significant homology with any other known sequences and gives a distinct signal in Northern blotting (Young et al., 1990) . The cDNA was subcloned in a Bluescript transcription vector and transcribed with high efficiency from the T3 or T7 promotors to generate sense and anti-sense cRNA. Linearized plasmid DNA was transcribed in the presence of [3'S]-UTF' 800 pCi/mmol (Amersham; Poole, UK). essentially as recommended by the manufacturer (Boehringer; Mannheim, FRG). Labeled RNA was separated from unincorporated nucleotides by precipitation and subjected to limited alkaline hydrolysis by incubation with 0.2 N NaOH on ice. Analytical gel electrophoresis was used to check the transcript size before and after hydrolysis.
The polyclonal antibody (U-BON-11) was raised in rabbits against purified bovine osteonectin. As described earlier, the antibody shows crossspecies activity and is specific for osteonectin (Jundt et al., 1987; Termine et al., 1981) .
In Situ Hybridization and Immunohistochemistry. For in situ hybridization, frozen sections were cut on a Leitz cryostat and were mounted on triethoxyethanolamine-treated microscopic slides. The slides were immersed in 4% paraformaldehyde in PBS for 10 min, followed by PBS for 5 min, 0.2 NHCl for 10 min, 2 x SSC at 50°C for 20 min. digestion with pronase (Boehringer) 0.3 mglml for 10 min at room temperature, 0.2% glycine in PBS for 5 min, fixation in paraformaldehyde 4% for 15 min. acetylation, and dehydration in graded series of ethanol. Probes were diluted to a specific activity of 10' cpml1.l in a hybridization buffer containing 50% formamide, 10% dextran sulfate, 0.3 M NaCI, 10 mM Tris, pH 7, 10 mM NaHP04, pH 5, 5.5 mM EDTA, 0.02% Denhardt's, and tRNA 0.5 mg/ml. The sense cRNA probe was used as a negative control. Approximately 30-50 p1 were used per slide. Hybridization was performed overnight at 47'C in a humidified chamber. Slides were washed in 50% formamide/SSC at 50°C for 2 hr, followed by incubation with RNAse 20 pg/ml (Sigma; Munich, FRG) for 15 min and SSC for three times for 30 min at RT. After dehydration, slides were dipped in Kodak NTB-2 emulsion diluted 1:1 with H20 and air-dried. Autoradiography was performed at 4'C in a dry chamber. Exposure time varied from 10-20 days. The exposed slides were developed, fixed, stained, and examined using the Zeiss system for epipolarization.
For immunohistochemistry, paraffin sections were mounted on triethoxyethanolamine-treated slides. To remove the bulk of mauix-associated proteoglycans, sections were treated with 5 mg/ml testicular hyaluronidase (Sigma, Type 1-S) for 1 hr at 37'C. The polyclonal anti-human antibody against osteonectin (LFBON-11) was used in dilutions of 1:lOO-1:200. The ABC method was applied and peroxidase was used as a marker enzyme. Conventional positive and negative controls were performed.
Results
A widespread distribution of osteonectin gene expression was found in embryonic and fetal tissue. Osteonectin reactivity was usually present in tissues undergoing rapid proliferation. Accordingly, earlier developmental stages showed a more general distribution. This pattern changed to a distinct heterogeneity in later stages (Table 1) . Figure 1B shows a section through an 8-week phalanx. Mesenchymal cells were osteonectin positive. As judged by grains/cell, the amount of specific mRNA was low but clearly above background activity. The perichondrium as well as the skin showed a high degree of osteonectin gene expression in areas that corresponded to rapid cell 
Distribution of Osteonectin in Developing Bone
Osteonectin expression preceded the calcification of cartilaginous matrix and was first detected parallel to the formation of hypertrophied chondrocytes at the diaphysis. At this stage, osteonectin protein was detected in hypertrophied chondrocytes as well as in the surrounding matrix ( Figure 2A ). Concurrently with the maturation of chondrocytes, a thin layer of bone is deposited at the diaphysis by newly formed osteoblasts. Figure 3B shows a section through a 7-week humerus (Stage 18) with strong expression in the perichondrium and osteoblasts. At this stage, osteonectin gene expression was less intense than in later stages of development. In addition, chondrocytes of the upper hypertrophic and proliferative zones were osteonectin positive, whereas hypertrophic chondrocytes undergoing calcification were osteonectin negative. This pattern of osteonectin gene expression was found throughout the following stages of development.
With further growth, the areas of calcified cartilaginous matrix expands and a regular bone collar is formed. At this stage (Weeks 9-10 of gestation; Figures 3C and 3D ), osteonectin gene expression was found in osteoblasts of the periosteum and, to a lesser degree, in fibroblasts of the perichondrium and in tendons. In chondrocytes, osteonectin mRNA was limited to the upper hypertrophic and proliferative zones, whereas the resting zone showed less staining. The osteonectin-negative area was clearly separated and corresponded to the area of calcification.
With further growth of the fetus, the area of diaphyseal calcification enlarges and hypertrophic chondrocytes are constantly removed and replaced by marrow. Figure 3F shows osteonectin gene expression in a section through the distal part of a 14-week femur.
Again, hypertrophic chondrocytes of the zone of calcification showed no osteonectin gene expression. Strong expression was present in osteoblasts, perichondrium, and ligaments.
At birth, a regular growth plate with hypertrophic cartilage arranged in columns has been formed (Figure 3G) teonectin gene expression was mainly found in chondrocytes of the upper hypertrophic and proliferative zones, whereas the resting cartilage and mineralized cartilage showcd no expression ( Figure 3H) .
A similar pattern was found at the epiphyseal zone of calcification.
In bones undergoing desmal ossification, osteonectin gene expression was primarily found in the areas of newly formed bone. The differentiation of osteoblasts to osteocytes was paralleled by the loss of osteonectin expression (Figures 31 and 3J ). In the developing spine, osteonectin expression was associated with the cells ofthe intervetebral disc anlagen and adjacent ligaments (not shown).
The corresponding immunohistochemistry confrmed the results and gave additional information on the extracellular distribution of osteonectin. Osteonectin protein was localized in osteoblasts of the periosteal sheet, in newly formed osteoid, and in bone. In chondrocytes. osteonectin appeared before the calcification of cartilaginous matrix in hypertrophic chondrocytes at the diaphysis (Figure 2A) . At this stage, staining was detected intra-and extracellularly.
With the calcification of matrix, intracellular staining was lost, corresponding to the results of the in situ hybridization study. However, extracellular staining persisted in the pre-mineralized and mineralized zones (Figure 2B) . A similar picture was observed in the epiphyseal growth plate.
Osteonectin in Developing Teeth
The human tooth develops beginning in the eighth week with the formation of a tooth bud. Around the twelfth week of development, the future tooth has a bell-like form. At this stage, the first dentin is built by newly formed odontoblasts. Osteonectin-specific mRNA was first detected at this stage and was linked to the production of dentin. Figure 4 shows a cross-section through a 15-week fetal premolar. Strongly positive cells were clearly identified as odontoblasts, whereas ameloblasts and undifferentiated pulpal cells showed no expression. Immunohistochemistry gave a similar picture. Osteonectin reactivity was limited to odontoblasts and their cell processes. No extracellular reactivity was detectable.
Osteonectin in the Developing Urogenital System
In the mesonephros, expression was found in the cells of the primitive glomeruli but not in adjacent structures (not shown). In the permanent kidney (metanephros), the nephrogenic blastema and the mesenchyme were only weakly positive. Osteonectin expression was linked to the development of the glomerulus. Specific mRNA was first detected in the cells of the inferior cleft of the S-shaped bodies ( Figure 5E ). Parallel with the formation of the mature glomerulus, the pattern of expression changed. Mesangial labeling increased progressively with glomerular maturation, resulting in an even distribution of osteonectin mRNA within cells of the developing podocyte layer and mesangial cells ( Figure 5G ). The distal tubule and the collection system remained negative. This pattern of expression was lost with birth. In spite of various pre-digestion treatments, no immunoreactivity was detected in the cells of the podocyte layer. Mesangial cells showed a weak reaction.
Male and female gonads showed a specific pattern of osteonectin gene expression dependent on the different stages of development. In the immature male gonad, expression was present in all cells but was strongest in the condensing tubules, corresponding to the precursors of the Sertoli cells and spermatogonia ( Figure 6B ). In the fetal and newborn testis, osteonectin reactivity was noted in the steroid-producing Leydig cells and to a low degree in spermatogonia ( Figure 6C ). In the ovary, a similar distribution was found. Osteonectin expression was linked to the precursors and the early stages of the oocyte (not shown).
Adrenal Gland
In situ hybridization and immunohistochemistry revealed a distinct heterogeneity in osteonectin distribution in the fetal adrenal gland (Figures SA-5C ). Reaction was strongest in the fetal cortex but was absent in the primordium of the permanent cortex. No expression was found in the medulla. Histochemistry confirmed these results and showed an intracellular distribution only.
Other Organs (Not Shown)
In the fetal liver, osteonectin expression was detected only in nonhepatocytes. Strong expression was seen in megakaryocytes and in cell clusters that were probably hematopoietic progenitors. In the lung, mRNA and immunoreactivity was present in the epithelial cells of bronchi and bronchioli. In the bone marrow, megacaryo- cytes showed a strong reaction. Strong expression was also present in the sclera of the developing eye. There was no obvious high level of osteonectin expression in neural tissue. Positive reaction was noted in the meninges and in the choroid plexus. No mRNAlimmunoreactivity was detected in thyroid, thymus, intestinal epithelium, and spleen.
Discussion
In the present study, the localization of osteonectin protein and mRNA is described during different stages of human development.
The combination of in situ hybridization and immunohistochemistry techniques revealed a distinct pattern of RNA and protein distribution that might help to clarify the role of osteonectin in these various organ systems.
The distribution of osteonectin in human tissues can be summarized as follows: (a) osteonectin was associated with tissues that exhibit high rates of cell proliferation and matrix production (skin, vessels, tendons, fetal mesenchyme, perichondrium); (b) osteonectin was particularly abundant in cells involved in the process of mineralization (osteoblasts, chondrocytes. odontoblasts); and (c) production of basement membranes (glomeruli) and steroid synthesis were associated with osteonectin expression. Immunohistochemistry confirmed the results obtained by in situ hybridization and gave additional information on the extracellular distribution of osteonectin. In the ECM, osteonectin was detectable only in tissues undergoing mineralization. In contrast to earlier studies in bovine tissue (Bianco et d., 1988) . osteonectin was not only detected in newly formed osteoid and bone but also in the cartilaginous matrix of the growth plate. In situ hybridization and histochemistry showed a strong mpression of osteonectin in chondrocytes of the proliferative and upper hypertrophic zones, whereas the zone of mineralization showed no expression. In the pre-mineralization zone osteonectin was detected solely intracellularly but appeared in the ECM a few cell layers before mineralization occurred. A similar pattern of intra-and extracellular distribution was described in chick tibial growth cartilage (Pacifici et al., 1990) . These findings support the proposed role of osteonectin as a regulatory protein of mineralization. The production of osteonectin in chondrocytes of the proliferative zone and its subsequent secretion in the ECM may prevent calcification in this zone. With the cessation of osteonectin expression, mineralization proceeds. In this respect it is of interest that chondrocytes of the mineralized zone also stop the production of Type I1 collagen (Mundlos et al., 1990) and proteoglycan (Mundlos et al., in press) and switch to other components of the ECM that promote calcification, such as Type X collagen (Schmidt and Linsenmayer, 1985) and alkaline phosphatase (Mundlos. unpublished observation) . In the developing tooth, osteonectin was detectable only intracellularly in odontoblasts. This might be due to different mechanisms of calcification in this tissue or to masking of epitopes.
The finding of osteonectin expression in the developing kidney is in agreement with the results of Northern blots published earlier (Metsaranta et al., 1989) . However, the results are in contrast to the findings in murine tissue where osteonectin-specific mRNA was not detectable in the developing kidney (Sage et al., 1989a, b) . In our study, osteonectin expression was first noted in the primitive glomeruli of the mesonephros and in association with the precursors of the presumptive glomeruli, the S-shaped bodies. In the S-shaped bodies, expression was observed exclusively in the cells of the developing podocyte layer. In contrast, in the mature glomerulus specific mRNA was detected in mesangial cells as well as in glomerular basement membrane-producing cells of the podocyte layer. These results are consistent with the changes in Type IV collagen distribution during glomerular maturation as described by Ekblom and others (Mounier et al.. 1986; Ekblom, 1981) . The association of osteonectin with the synthesis of basement membranes has been reported in tissues such as well-differentiated human carcinomas and endometrial cells of the deciduum (Wewer et al., 1988) . The present findings suggest a specific role for osteonectin during formation of basement membranes in kidney development.
High levels of osteonectin expression appeared to be correlated with steroid production. In the adrenal gland, the fetal cortex showed high levels of osteonectin proteinlRNA. Leydig cells of the testis also involved in steroid production showed osteonectin expression. These results are in agreement with the expression found in murine tissue (Sage et al., 1989a,b; Holland et al., 1987) .
The widespread distribution of osteonectin shown in this study argues for a general role of osteonectin in the regulation of matrixlcell membrane production. The Ca++ binding properties of osteonectin, recently supported by the analysis of osteonectin peptide sequence (Bolander et al., 1988) , suggest an interaction of osteonectin with other Ca++-sensitive proteins. In bone and cartilage, this interaction might take place intracellularly but is certainly present in the surrounding ECM. As our results suggest, osteonectin acts as a regulator in the initiation of mineralization in the cartilaginous matrix of the growth plate. In other organ systems where osteonectin was located only intracellularly, the function may be different. As reported by Sage et al. (1986) , osteonectin is an inhibitor of cell spreading and therefore may be required to modulate cell interactions with the ECM. The expression of osteonectin may be one mechanism by which proliferating cells can diminish adhesive interactions with their substrate (Lane and Sage, 1990) .
Its anti-spreading activity may represent a basic role for osteonectin in proliferating tissue but gives no explanation for the heterogeneity of osteonectin expression in other organs. In the adrenal gland, osteonectin mRNAlprotein was detected in large amounts in the fetal cortex but not in the permanent cortex or the medulla.
Here, osteonectin expression seemed to be linked to the production of cell-specific products (steroids) rather than to the rate of cell proliferation. A similar picture was seen in the developing gonad. With increasing differentiation, the general expression of osteonectin was lost and changed to a specific expression in cells that are not primarily involved in proliferation (Leydig cells). Osteonectin expression was clearly linked to proliferation, as documented by the generalized distribution during embryonic and early fetal development. However, in later stages the function-specific distribution in mineralized tissue, glomeruli, steroid-producing cells, and megakaryocytes suggests a multifunctional role of this protein.
